Clinical trials: Oxaliplatin, open to volunteers
Diffuse Large B-Cell Lymphoma
Evaluation of the Efficacy and Safety of Polatuzumab Vedotin Combined With Rituximab, Gemcitabine, and Oxaliplatin (Pola-R-GemOx) as Salvage Therapy for Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Patients Ineligible for Autologous Transplantation
This is a prospective, multicenter, single-arm clinical study designed to evaluate the efficacy and safety of Polatuzumab Vedotin combined with Rituximab, Gemcitabine, and Oxaliplatin (Pola-R-GemOx) as salvage therapy for…
- Trial name
- NCT07001540
- Testing
- Polatuzumab Vedotin combined with Rituximab, Gemcitabine, and Oxaliplatin (Pola-R- GemOx)
- Where
- China
- Volunteers
- 130 people
- Sponsor
- Fudan University
Intrahepatic Cholangiocarcinoma (Icc), Neoadjuvant Therapy
Perioperative Retlirafusp Alfa(Anti-PD-L1/TGF-β Bifunctional Fusion Protein) Plus Famitinib and GEMOX-Based Hepatic Arterial Infusion Chemotherapy for Locally Advanced Intrahepatic Cholangiocarcinoma: A Multicenter, Single-Arm, Exploratory Phase II Trial
This is a multicenter, single-arm, exploratory clinical study for adults with locally advanced intrahepatic cholangiocarcinoma (ICC) that may be technically resectable but is difficult to remove directly by surgery.
- Trial name
- H-FROG (NCT07847710)
- Testing
- Retlirafusp alfa, Famitinib malate, Gemcitabine & oxaliplatin
- Where
- China
- Volunteers
- 81 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Colon Cancer, Rectal Cancer
CGA Guided Ultrafractionated RT and First-line Systemic Treatment in Elderly or Frail Patients with MCRC
This is a prospective, multicentre, cohort study. For cohort 1(CGA cohort), experimental cohort, older or Frail patients with metastatic colorectal cancer will receive Ultrafractionated Radiotherapy (RT) and Comprehensive…
- Trial name
- NCT06665087
- Testing
- Ultrafractionated RT and CGA Guided systemic treatment., Ultrafractionated Radiotherapy, PD-1 antibody
- Volunteers
- 110 people
- Sponsor
- Fudan University
Colorectal Cancer
The Role of Coenzyme Q10 in the Prophylaxis of Oxaliplatin Induced Peripheral Neuropathy in Patients With Colorectal Cancer
This study aims to evaluate the possible beneficial role of coenzyme Q10 against oxaliplatin-induced peripheral neuropathy in patients with colorectal cancer.
- Trial name
- NCT06856447
- Testing
- Coenzyme Q10, Oxaliplatin, 5-Fluorouracil (5-FU)
- Where
- Egypt
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- toqa saad mohammed mohammed
High-risk Stage II Colorectal Cancer, Stage III Colorectal Cancer
Circulating Tumor DNA Methylation Guided Postoperative Adjuvant Chemotherapy for High-risk Stage II/III Colorectal Cancer
Colorectal cancer (CRC) is one of the most common gastrointestinal tumors. According to the latest cancer report, the incidence and mortality rates of CRC are both ranked top 5 among malignant tumors worldwide and continue to…
- Conditions
- High-risk Stage II Colorectal Cancer, Stage III Colorectal Cancer, Circulating Tumor DNA Methylation
- Trial name
- NCT05954078
- Testing
- mFOLFIRINOX adjuvant chemotherapy, mFOLFOX6/XELOX adjuvant chemotherapy
- Where
- China
- Volunteers
- 340 people
- Sponsor
- Fudan University
Advanced Rectal Cancer, Liver Metastasis
A Combination Therapy Including Anti-PD-1 Immunotherapy in MSS Rectal Cancer With Resectable Distal Metastasis
Although patients with locally advanced rectal cancer and resectable liver/pulmonary metastasis could benefit from surgery resection, these patients still have a poorer prognosis compared to those without distal metastasis.
- Conditions
- Advanced Rectal Cancer, Liver Metastasis, Pulmonary Metastasis, Microsatellite Stable Colorectal Carcinoma
- Trial name
- Miracle-1 (NCT05359393)
- Testing
- a combination therapy including tislelizumab
- Where
- China
- Volunteers
- 52 people
- Sponsor
- Fudan University
Metastatic Pancreatic Cancer
Metronomic Capecitabine, Oxaliplatin and UGT1A1 Genotype-directed Irinotecan in Metastatic Pancreatic Cancer Patients
This is a single-centre, non-randomized, open label phase II trial to be conducted at the National Cancer Centre, Singapore (NCCS). Patients diagnosed with metastatic PDAC will be eligible to enrol.
- Trial name
- NCT05929885
- Testing
- Low Dose OXIRI (LD-OXIRI)
- Where
- Singapore
- Volunteers
- 50 people
- Sponsor
- National Cancer Centre, Singapore
Gastric Cancer Stage III
QL1706-SOX vs SOX Alone as Neoadjuvant Therapy for Resectable Diffuse-Type Gastric Cancer
The goal of this randomized, open-label, phase II clinical trial is to determine whether adding the PD-1/CTLA-4 bispecific antibody QL1706 to standard SOX chemotherapy increases the pathological complete response rate in adults…
- Trial name
- NCT07315035
- Testing
- QL1706 (Iparomlimab/Tuvonralimab), SOX Chemotherapy
- Where
- China
- Volunteers
- 74 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Metastatic Colorectal Carcinoma
A Clinical Trial of LBL-024 Combination Drug in Patients With Metastatic Colorectal Carcinoma
This study is an open-label, multi-center Phase Ib/II clinical trial evaluating the safety and efficacy of LBL-024 in combination with other drugs for the treatment of metastatic colorectal carcinoma (mCRC), aiming to evaluate…
- Trial name
- NCT07791758
- Testing
- LBL-024 for Injection, Bevacizumab injection, Oxaliplatin injection
- Where
- 10 sites in China
- Volunteers
- 369 people
- Sponsor
- Nanjing Leads Biolabs Co.,Ltd
Locally Advanced Rectal Cancer, Older People
Efficacy and Safety of Conventional Neoadjuvant Therapy Versus Total Neoadjuvant Therapy in Older Patients With Locally Advanced Rectal Cancer
The SHAPERS study is a multicentre, open-label, randomised, pragmatic clinical trial, comparing standard-of-care neoadjuvant treatment options for older (i.e., ≥70 years) subjects with high-risk stage II and stage III rectal…
- Trial name
- SHAPERS (NCT06052332)
- Testing
- Short course radiotherapy, Adjuvant chemotherapy (optional), Total mesorectal excision
- Where
- 19 sites in Belgium
- Volunteers
- 230 people
- Sponsor
- Jules Bordet Institute
Hepatobiliary Malignancy, Fluoxetine
SSRI Antidepressant Fluoxetine Improving Immunotherapy Efficacy in Advanced Hepatobiliary Malignancy Patients With Depression and Anxiety
Advanced liver and gallbladder malignancies (including liver cancer, cholangiocarcinoma and gallbladder cancer) are a type of disease that is difficult to treat, and most patients have a short survival period.
- Conditions
- Hepatobiliary Malignancy, Fluoxetine, Anxiety Disorders, Depression Disorders
- Trial name
- NCT07174947
- Testing
- Fluoxetine (drug)
- Where
- China
- Volunteers
- 240 people
- Sponsor
- First Affiliated Hospital of Wenzhou Medical University
Gastric Adenocarcinoma and Gastroesophageal Junction Adenocarcinoma
Retlirafusp Alfa Injection Plus Chemotherapy Versus Investigator's Choice of Anti-PD-1 Antibody Plus Chemotherapy as First-line Treatment for Advanced Gastric Cancer With Liver Metastases
This study is a randomized, controlled, open-label phase III clinical trial, aims to compare the efficacy and safety of Retlirafusp alfa injection plus CAPOX versus the investigator's choice of anti-PD-1 antibody plus CAPOX as…
- Trial name
- NCT07677293
- Testing
- Retlirafusp alfa Injection, Capecitabine, Oxaliplatin
- Volunteers
- 332 people
- Sponsor
- Peking University
Biliary Tract Cancer
Sintilimab Plus NALIRIFOX or Gemcitabine-Cisplatin as First-Line Treatment for Metastatic Biliary Tract Cancer
This is a randomized, noncomparative, open-label, exploratory clinical study designed to evaluate the efficacy and safety of sintilimab in combination with NALIRIFOX or gemcitabine plus cisplatin (GP) as first-line treatment for…
- Trial name
- NCT07831993
- Testing
- Sintilimab, Irinotecan Hydrochloride Liposome Injection (II), Oxaliplatin
- Where
- China
- Volunteers
- 54 people
- Sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Metastatic HER2 Positive Gastroesophageal Junction Cancer
Cadonilimab Combination Regimen as First-line Treatment for HER2-expressing GC/GEJ Patients
This trial is An open-label, multicohort, multicenter clinical study aimed at evaluating the efficacy and safety of the cadonilimab combination regimen in the treatment of advanced HER-2 positive gastric/gastroesophageal junction…
- Trial name
- NCT06650332
- Testing
- cadonilimab, Trastuzumab, XELOX
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Zhejiang Cancer Hospital
Gastric Cancer, Survival Rate
Effect of HIPEC After Radical Surgery on Long-term Survival for Locally Advanced Gastric Cancer
The study focuses on patients with locally advanced gastric adenocarcinoma (cT3N+M0 and cT4aN+/-M0), assessing the feasibility, surgical safety, and oncological benefit of prophylactic HIPEC treatment following laparoscopic D2…
- Trial name
- NCT06525714
- Testing
- cisplatin oxaliplatin tegafur
- Volunteers
- 302 people, healthy volunteers welcome
- Sponsor
- The First Hospital of Jilin University
Gastric Cancer (Including Stomach and Gastroesophageal Junction [GEJ]), Neoadjuvant Therapy
Neoadjuvant Cadonilimab Combined With Perioperative Oxaliplatin Plus S1 for Diffuse or Mixed Type of Locally Advanced Gastric/Gastroesophageal Junction Adenocarcinoma
This study aims to investigate the efficacy and safety of neoadjuvant cadonilimab in combination with perioperative SOX chemotherapy, compared to perioperative SOX chemotherapy alone, in patients with diffuse or mixed-type…
- Conditions
- Gastric Cancer (Including Stomach and Gastroesophageal Junction [GEJ]), Neoadjuvant Therapy, Adjuvant Chemotherapy, pCR Rate
- Trial name
- NCT06949033
- Testing
- Neoadjuvant cadonilimab combined with perioperative SOX
- Where
- 4 sites in China
- Volunteers
- 668 people
- Sponsor
- Zuoyi Jiao
Peripheral Neuropathy Due to Chemotherapy
Compression Therapy of Hands and Feet for the Prevention of Taxane- or Oxaliplatin-induced Peripheral Neuropathy
Population Cohort 1 Taxane: Breast cancer patients; (neo-)adjuvant treatment Cohort 2 Oxaliplatin: Colorectal cancer patients; (neo-)adjuvant treatment Study design Multicentre, unblinded randomised controlled study Study…
- Trial name
- KompXX (NCT07464769)
- Testing
- Compression therapy
- Where
- Sweden
- Volunteers
- 358 people
- Sponsor
- Region Jönköping County
Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Study Comparing BEBT-908 Combined With R to SOC for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma
This is a multicenter, randomized, controlled, open-label Phase III clinical trial, aimed at evaluating the efficacy and safety of BEBT-908 combined with rituximab (R) compared to investigator-selected standard chemotherapy…
- Trial name
- NCT06792253
- Testing
- Ifupinostat Hydrochloride for Injection, Rituximab Injection, Gemcitabine Hydrochloride for Injection
- Where
- China
- Volunteers
- 416 people
- Sponsor
- BeBetter Med Inc
Clinical Stage IV Gastric Cancer AJCC v8, Clinical Stage IVA Gastric Cancer AJCC v8
PIPAC for the Treatment of Peritoneal Carcinomatosis in Patients With Ovarian, Uterine, Appendiceal, Colorectal, or Gastric Cancer
This phase I trial studies the side effects of pressurized intraperitoneal aerosol chemotherapy (PIPAC) in treating patients with ovarian, uterine, appendiceal, stomach (gastric), or colorectal cancer that has spread to the…
- Conditions
- Clinical Stage IV Gastric Cancer AJCC v8, Clinical Stage IVA Gastric Cancer AJCC v8, Clinical Stage IVB Gastric Cancer AJCC v8, Malignant Uterine Neoplasm
- Trial name
- NCT04329494
- Testing
- Biopsy, Cisplatin, Doxorubicin
- Where
- 3 sites in United States
- Volunteers
- 49 people
- Sponsor
- City of Hope Medical Center
Hepatocellular Carcinoma
The Impact on Survival of Neo-adjuvant Transarterial Chemoinfusion (TAI) for Patients With Hepatocellular Carcinoma And Portal Vein Tumor Thrombosis (PVTT) Who Underwent Hepatectomy : A Random, Controlled, Stage III Clinical Trial.
To compare the impact on survival of neo-adjuvant TAI for patients with HCC and PVTT who underwent hepatectomy.
- Trial name
- NCT03368651
- Testing
- TAI
- Where
- China
- Volunteers
- 230 people
- Sponsor
- Sun Yat-sen University